Exact Sciences (EXAS) CEO reports RSU vesting and tax-withheld share dispositions
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Exact Sciences President and CEO Kevin T. Conroy reported multiple equity compensation events involving restricted stock units and common stock. On February 27, 2026, several restricted stock unit awards vested, each unit representing a right to receive one share of common stock.
Upon vesting, Mr. Conroy acquired corresponding shares of common stock through derivative exercises, and the company retained blocks of 8,528, 10,419, and 13,060 shares at $103.25 per share for tax withholding purposes. After these transactions, he directly held 1,278,045 shares in various accounts and plans, plus additional indirect holdings.
A footnote states that, in addition to the common shares reported, Mr. Conroy also holds an aggregate of 737,129 vested and unvested options and restricted stock units, each unit representing a contingent right to receive one share of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
68,097 shares exercised/converted
Mixed
13 txns
Insider
Conroy Kevin T
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 18,143 | $0.00 | -- |
| Exercise | Restricted Stock Units | 22,168 | $0.00 | -- |
| Exercise | Restricted Stock Units | 27,786 | $0.00 | -- |
| Exercise | Common Stock | 18,143 | $0.00 | -- |
| Tax Withholding | Common Stock | 8,528 | $103.25 | $881K |
| Exercise | Common Stock | 22,168 | $0.00 | -- |
| Tax Withholding | Common Stock | 10,419 | $103.25 | $1.08M |
| Exercise | Common Stock | 27,786 | $0.00 | -- |
| Tax Withholding | Common Stock | 13,060 | $103.25 | $1.35M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 18,143 shares (Direct);
Common Stock — 1,260,098 shares (Direct);
Common Stock — 29,061 shares (Indirect, Held in 401(k) Plan)
Footnotes (1)
- Represents shares of common stock received upon vesting of a restricted stock unit award. Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. In addition to the shares of Common Stock reported on this Form 4, which total 1,557,821 shares, Mr. Conroy also holds, in the aggregate, an additional 737,129 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Each restricted stock unit represents a contingent right to receive one share of common stock. Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. Represents a restricted stock unit award granted on February 24, 2025 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February.
FAQ
What did Exact Sciences (EXAS) CEO Kevin Conroy report on this Form 4?
Kevin Conroy reported vesting of restricted stock units and related issuances of Exact Sciences common stock. Shares were delivered upon RSU vesting, while a portion was retained by the company to cover tax withholding obligations tied to these equity awards.
How were restricted stock units for Exact Sciences (EXAS) CEO settled?
Restricted stock units were settled in Exact Sciences common stock when they vested. Each unit represents a contingent right to receive one share, and several grants partially vested on February 27, 2026, consistent with their four-year annual vesting schedules.
Were the Exact Sciences (EXAS) Form 4 transactions open-market buys or sales?
The reported Form 4 activity reflects equity award vesting, exercises, and tax withholding, not open-market trades. Common stock was issued upon restricted stock unit vesting, and some shares were withheld by Exact Sciences to pay related tax liabilities.
What do the vesting schedules mean for Exact Sciences (EXAS) CEO equity awards?
The footnotes explain that RSU awards granted in 2023, 2024 and 2025 vest in four equal annual installments. Each vests on the last trading day of February, meaning additional portions will vest in future years if service-based conditions continue to be satisfied.